Seward announces merger and restructuring plans to establish FermionX Ltd
Merger with sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company.
Seward, makers of Stomacher laboratory blenders and Insterprep sterile media, has merged with its sister company, C-Tech Electronics Ltd, to form a new vertically integrated manufacturing company called FermionX Ltd. There will be no change to Seward’s name; and its high standard of operations known and expected by its customers will also remain the same, but with the added benefit of increased technical resource for R&D, customer support and manufacturing.
The merger represents a significant development for stakeholders, creating a company with combined turnover of circa £6 million. This move consolidates two companies with shared core values on strong customer relationships, quality and value-added products and service.
FermionX will continue to operate through its individual brands; Seward, manufacturers of globally renowned Stomacher lab blenders, and C-Tech Electronics, providing comprehensive electronic contract manufacturing services. The company will leverage both brands’ respective strengths for the benefit of its customers with greater resources for manufacturing, R&D and global sales and distribution footprint.
The merger provides a greater technical resource for Seward to enhance its R&D strategy, an area which has gained emphasis recently with the launch of the Stomacher 400 EVO laboratory blender and Insterprep range of pre-weighed, sterile media.
Under the C-Tech Electronics brand, the company has a highly successful and flexible manufacturing service, providing comprehensive contract electronic manufacturing solutions with expertise and experience from PCB design to complete box-build.
The new company will be led by John Patrick, whose family started C-Tech Electronics. Mr Patrick said: “Establishing FermionX Ltd is an immensely exciting step, developing a company that can provide end-to-end electronic manufacturing solutions, with a final product mind-set. The consolidated resource from all companies will allow us to quickly respond to market opportunities and technology trends to better support our customers.” He added: “While FermionX provides the overriding corporate structure, all company brands will continue to be presented under their existing brand names and to the same high standards of products and service.”
Former Managing Director of Seward, Daniel Crothers, remains with the company as Sales and Marketing Director. Mr Crothers continued: “Seward enjoys a global reputation for quality laboratory products. Under FermionX, the Seward brand will continue to enhance this reputation with emphasis on new product development that adds real value to our laboratory customers. We already have a project list for planned launches in 2017 which our distribution partners are very excited about.”
Technical Director Stuart Ray, who will be heading up the R&D team said: “Both companies have collaborated over the years on product design and development with customers and other strategic partners, FermionX will allow this function to expand and drive the growth of our brands and of the business in general.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.